These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Development of a Histopathology Informatics Pipeline for Classification and Prediction of Clinical Outcomes in Subtypes of Renal Cell Carcinoma. Marostica E; Barber R; Denize T; Kohane IS; Signoretti S; Golden JA; Yu KH Clin Cancer Res; 2021 May; 27(10):2868-2878. PubMed ID: 33722896 [TBL] [Abstract][Full Text] [Related]
29. Renal cell carcinoma and proteomics. Sandim V; Pereira DA; Ornellas AA; Alves G Urol Int; 2010; 84(4):373-7. PubMed ID: 20224258 [TBL] [Abstract][Full Text] [Related]
30. Low NR3C2 levels correlate with aggressive features and poor prognosis in non-distant metastatic clear-cell renal cell carcinoma. Zhao Z; Zhang M; Duan X; Deng T; Qiu H; Zeng G J Cell Physiol; 2018 Oct; 233(10):6825-6838. PubMed ID: 29693713 [TBL] [Abstract][Full Text] [Related]
31. ERCC6L that is up-regulated in high grade of renal cell carcinoma enhances cell viability in vitro and promotes tumor growth in vivo potentially through modulating MAPK signalling pathway. Zhang G; Yu Z; Fu S; Lv C; Dong Q; Fu C; Kong C; Zeng Y Cancer Gene Ther; 2019 Sep; 26(9-10):323-333. PubMed ID: 30459398 [TBL] [Abstract][Full Text] [Related]
32. Upregulated GSDMB in Clear Cell Renal Cell Carcinoma Is Associated with Immune Infiltrates and Poor Prognosis. Cui Y; Zhou Z; Chai Y; Zhang Y J Immunol Res; 2021; 2021():7753553. PubMed ID: 34957313 [TBL] [Abstract][Full Text] [Related]
33. TRPM7 Regulates AKT/FOXO1-Dependent Tumor Growth and Is an Independent Prognostic Indicator in Renal Cell Carcinoma. Zhao Z; Zhang M; Duan X; Chen Y; Li E; Luo L; Wu W; Peng Z; Qiu H; Zeng G Mol Cancer Res; 2018 Jun; 16(6):1013-1023. PubMed ID: 29545479 [TBL] [Abstract][Full Text] [Related]
34. TFEB Mediates Immune Evasion and Resistance to mTOR Inhibition of Renal Cell Carcinoma via Induction of PD-L1. Zhang C; Duan Y; Xia M; Dong Y; Chen Y; Zheng L; Chai S; Zhang Q; Wei Z; Liu N; Wang J; Sun C; Tang Z; Cheng X; Wu J; Wang G; Zheng F; Laurence A; Li B; Yang XP Clin Cancer Res; 2019 Nov; 25(22):6827-6838. PubMed ID: 31383732 [TBL] [Abstract][Full Text] [Related]
35. Cannabinoid receptor 2 as a novel target for promotion of renal cell carcinoma prognosis and progression. Wang J; Xu Y; Zhu L; Zou Y; Kong W; Dong B; Huang J; Chen Y; Xue W; Huang Y; Zhang J J Cancer Res Clin Oncol; 2018 Jan; 144(1):39-52. PubMed ID: 28993942 [TBL] [Abstract][Full Text] [Related]
36. Genomics of renal cell cancer: the biology behind and the therapy ahead. Jones J; Libermann TA Clin Cancer Res; 2007 Jan; 13(2 Pt 2):685s-692s. PubMed ID: 17255294 [TBL] [Abstract][Full Text] [Related]
37. Perivascular Neuropilin-1 expression is an independent marker of improved survival in renal cell carcinoma. Morin E; Lindskog C; Johansson M; Egevad L; Sandström P; Harmenberg U; Claesson-Welsh L; Sjöberg E J Pathol; 2020 Apr; 250(4):387-396. PubMed ID: 31880322 [TBL] [Abstract][Full Text] [Related]
39. Protein expression of ZEB2 in renal cell carcinoma and its prognostic significance in patient survival. Fang Y; Wei J; Cao J; Zhao H; Liao B; Qiu S; Wang D; Luo J; Chen W PLoS One; 2013; 8(5):e62558. PubMed ID: 23658743 [TBL] [Abstract][Full Text] [Related]
40. Identification of a New Prognostic Risk Signature of Clear Cell Renal Cell Carcinoma Based on N Zhang Y; Yao Y; Qi X; Li J; Liu M; Che X; Xu Y; Wu G J Immunol Res; 2021; 2021():6617841. PubMed ID: 33628845 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]